公开(公告)号：US20090208521A1

公开(公告)日：2009-08-20

申请号：US12097895

申请日：2006-12-28

申请人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Agustin Lage Castellanos ,  Daniel Yero Corona ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

发明人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Agustin Lage Castellanos ,  Daniel Yero Corona ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

IPC分类号： A61K39/095 ,  A61K38/16 ,  A61P37/04

CPC分类号： A61K39/095 ,  A61K39/385 ,  A61K2039/55555 ,  A61K2039/6068 ,  C07K14/22 ,  C12Q1/6883

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical formulations containing NMA0939 protein. Formulations described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. NMA0939 protein was identified as a Neisseria meningitidis outer membrane vesicle component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMA0939 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulations presented in this invention are applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMA0939蛋白质的药物制剂的开发。 在本发明中描述的制剂能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMA0939蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡成分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMA0939编码基因表现出高水平的保守性，含有这种蛋白质的药物组合物作为交叉反应性免疫应答的诱导剂具有很高的价值。 本发明提出的制剂适用于人类医学领域。

公开(公告)号：US20090297547A1

公开(公告)日：2009-12-03

申请号：US12295436

申请日：2007-03-29

申请人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

发明人： Rolando Pajon Feyt ,  Gretel Sardinas Garcia ,  Darien Garcia Diaz ,  Sonia Gonzalez Blanco

IPC分类号： A61K39/12 ,  C12Q1/68 ,  G01N33/53 ,  A61K38/16 ,  C07K14/22

CPC分类号： A61K39/095 ,  A61K2039/6068 ,  C07K14/22

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical formulation containing NMB0938 protein. Formulation described in this invention is able to confer protection against different diseases caused or not by pathogenic agents. NMB0938 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation the NMB0938 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. Formulation presented in this invention is applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMB0938蛋白质的药物制剂的开发。 本发明描述的制剂能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB0938蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB0938编码基因的保守程度高，含有这种蛋白质的药物组合物具有高价值作为交叉反应性免疫应答的诱导剂。 本发明提出的制剂适用于人类医学领域。

公开(公告)号：US20100172931A1

公开(公告)日：2010-07-08

申请号：US12664278

申请日：2008-06-16

申请人： Rolando Pajon Feyt ,  Olivia Niebla Perez ,  Gretel Sardinas Garcia ,  Sonia Gonzalez Blanco ,  Darien Garcia Diaz ,  Evelin Caballero Menendez ,  Karem Cobas Acosta

发明人： Rolando Pajon Feyt ,  Olivia Niebla Perez ,  Gretel Sardinas Garcia ,  Sonia Gonzalez Blanco ,  Darien Garcia Diaz ,  Evelin Caballero Menendez ,  Karem Cobas Acosta

IPC分类号： A61K39/095 ,  C07K14/22 ,  A61K39/385 ,  C12Q1/02 ,  A61P31/04

CPC分类号： A61K39/095 ,  A61K2039/55583

摘要： The present invention is related to field of medicine, particularly to the development of pharmaceutical composition containing the NMB1796 protein. The composition described in this invention are able to confer protection against different diseases caused or not by pathogenic agents. The NMB1796 protein was identified as a Neisseria meningitidis outer membrane vesicle (OMV) component, and it was obtained through recombinant DNA technology being its immunogenicity and protective activity evaluated in animal models. Due to the high level of conservation that the NMB1796 coding gene has shown, pharmaceutical compositions containing this protein have a high value as inducers of a cross-reactive immune response. The composition presented in this invention is applicable to the field of human medicine.

摘要翻译： 本发明涉及药物领域，特别涉及含有NMB1796蛋白质的药物组合物的开发。 本发明中描述的组合物能够赋予针对由病原体引起或不由病原体引起的不同疾病的保护作用。 NMB1796蛋白被鉴定为脑膜炎奈瑟氏球菌外膜囊泡（OMV）组分，通过重组DNA技术获得其在动物模型中评估的免疫原性和保护活性。 由于NMB1796编码基因表现出高度的保守性，含有该蛋白质的药物组合物具有作为交叉反应性免疫应答诱导剂的高价值。 本发明提供的组合物可应用于人类医学领域。